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461REPLY: When is TAVR in Patients With
Severe Aortic Stenosis Deemed Extreme Risk
for Surgery Appropriate?We thank Dr. Philip for his interest in our paper (1).
Frail, elderly patients often have competing risks for
mortality or poor quality of life. We have shown that
patients with severe, symptomatic aortic stenosis in
whom surgery is not an option can experience not
only prolongation of life, but also improvement in
quality through 1 and 2 years (2). Our report showed
that mortality rates at 2 years following transcatheter
aortic valve replacement (TAVR) are improving, and
others have shown that mortality rates were favorable
to medical therapy alone (3). As pointed out by our
reader, Osnabrugge et al. (2) reported on health status
to 1 year from this same trial, and showed that posi-
tive predictors of poor outcomes included frailty and
disability measures, which were ﬁrst prospectively
collected in our study. Hermiller et al. recently re-
ported at the Annual Meeting of the American College
of Cardiology from a larger CoreValve US Pivotal Trial
dataset (N ¼ 3,687) similar predictors of mortality that
also included frailty and disability measures, such as
hypoalbuminemia, wheelchair bound, or on home
oxygen (4). These reports are encouraging because
they aid in assessing proper patient selection for
TAVR. Thorough discussion with all patients that in-
cludes the risks and beneﬁts of TAVR is standard of
care, and we are encouraged that with continued re-
ports from ongoing and future clinical trials and with
evolution of technology that treating elderly, frail
patients with TAVR will remain a reasonable option.The treatment for inoperable aortic stenosis, which
is certainly a terminal disease, has been established
with TAVR. This treatment option is a great advance
in medical therapy that should be offered to those
patients who, through careful selection, will have
improved quality of life.*Steven J. Yakubov, MD
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